Followers | 116 |
Posts | 8987 |
Boards Moderated | 0 |
Alias Born | 10/29/2017 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, March 08, 2019 10:06:05 AM
Date : 03/08/2019 @ 8:00AM
Source : GlobeNewswire Inc.
Stock : Selecta Biosciences, Inc. (SELB)
Quote : 2.57 0.54 (26.60%) @ 9:50AM
Selecta Biosciences to Report Fourth Quarter and Year End 2018 Financial Results and Provide Corporate Update
Alert
SELECTA BIOSCIENCES INC (NASDAQ:SELB)
Intraday Stock Chart
Today : Friday 8 March 2019
Click Here for more SELECTA BIOSCIENCES INC Charts.
Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced that it will report its fourth quarter full year end 2018 financial results and provide a corporate update before the open of the U.S. financial markets on Friday, March 15, 2019.
At 8:30 a.m. ET that day, Selecta will host a conference call and live audio webcast to discuss the year end 2018 financial results and provide a corporate update. Investors and the public can access a live and archived webcast of this call via the Investors & Media section of the company’s website, http://selectabio.com. Individuals may also participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10127200.
About Selecta Biosciences, Inc.
Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform. Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity. The company’s current proprietary pipeline includes ImmTOR-powered therapeutic enzyme and gene therapy product candidates. SEL-212, the company’s lead product candidate, is being developed to treat chronic refractory gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta’s proprietary gene therapy product candidates are in preclinical development for certain rare inborn errors of metabolism and incorporate ImmTOR with the goal of addressing barriers to repeat administration. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing of future events. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to those set forth in the “Risk Factors” section of Selecta’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on November 8, 2018, and in other filings that Selecta makes with the SEC. In addition, any forward-looking statements included in this press release represent Selecta’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Selecta specifically disclaims any obligation to update any forward-looking statements included in this press release.
Investors:
Sarah McCabe
Stern Investor Relations, Inc.
+1-212-362-1200
sarah@sternir.com
Media:
Lauren Tortorete
Spectrum Science Communications, Inc.
+1-212-468-5379
ltortorete@spectrumscience.com
Recent SELB News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/02/2024 10:30:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 11:54:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 11:08:48 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 11:06:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:03:48 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/26/2024 01:09:18 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/26/2024 11:57:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2024 10:25:14 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/19/2024 08:49:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/11/2024 01:47:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/11/2024 01:43:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/11/2024 01:35:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/11/2024 01:33:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/11/2024 01:30:50 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 04/10/2024 08:29:01 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 04/10/2024 08:25:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2024 08:20:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2024 11:00:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2024 08:32:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/28/2024 09:00:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/14/2024 11:55:09 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 12:08:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 12:06:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 12:05:20 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/14/2024 10:27:24 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM